Cannabis-Based Medical Products Show Promise for Long-Term Improvement in Insomnia Symptoms, New Study Finds
A groundbreaking observational study published in PLOS Mental Health on August 27, 2025, provides novel insights into the potential of cannabis-based medicinal products to improve sleep quality in patients suffering from insomnia. Conducted by researchers at Imperial College London and affiliated institutions, the investigation monitored 124 patients over an extended period of up to 18 months, signaling promising long-term benefits that transcend the typical short-term scope of insomnia treatment studies.
Insomnia and sleep disturbances affect roughly one-third of the global population at some point in their lives, with approximately 10 percent meeting the clinical criteria for insomnia disorder—a condition characterized by chronic difficulty in initiating or maintaining sleep that significantly impairs daytime functioning. Conventional pharmacological treatments, such as benzodiazepines or non-benzodiazepine hypnotics, often pose risks including tolerance, dependence, and adverse side effects, leaving a critical need for safer and more effective therapies.
Exploring cannabis-based medicinal products as an alternative treatment, the researchers analyzed patient-reported outcomes, focusing on subjective sleep quality, levels of anxiety and depression, and overall quality of life. These metrics provide a comprehensive understanding of how insomnia and associated symptoms respond to cannabis-based interventions over a substantial timeframe. The observational design of the study offers real-world evidence while acknowledging the necessity for future randomized controlled trials to confirm causality and further validate efficacy.
Patients enrolled in the study demonstrated significant, sustained improvements in self-reported sleep quality throughout the duration of the study. Notably, these benefits persisted for up to 18 months, suggesting that cannabis-based products may mitigate the issues of tolerance and diminishing effects observed with many traditional hypnotics. This sustained improvement points to a promising role for cannabinoids in sleep regulation pathways, potentially involving interactions with the endocannabinoid system, which is known to influence circadian rhythms and sleep architecture.
In addition to enhancements in sleep, the study participants showed marked reductions in anxiety and depression symptoms, conditions frequently comorbid with insomnia that exacerbate sleep difficulties. Such improvements are particularly relevant because psychoactive cannabinoids like THC and non-intoxicating compounds such as CBD have demonstrated anxiolytic and mood-stabilizing properties in other clinical contexts, implying a multifaceted therapeutic profile for medical cannabis in neuropsychiatric symptom management.
Pain—a notable contributor to sleep disruption—also lessened significantly among the study cohort. Chronic pain conditions often interfere with the onset and maintenance of restful sleep, and cannabinoids have been widely studied for their analgesic properties. The dual action on pain and sleep disturbances might explain the observed comprehensive improvements and highlight the potential for cannabis formulations tailored to complex symptom clusters.
Side effects associated with cannabis-based medicinal treatment were reported by approximately nine percent of patients, including fatigue, insomnia paradoxically, and dry mouth. Importantly, none were life-threatening or severe enough to warrant discontinuation in most cases. These findings underscore that while not without risk, the safety profile of cannabis-based products may compare favorably to that of conventional hypnotics, which often carry risks of dependence, cognitive impairment, and other adverse outcomes.
Dr. Simon Erridge, Research Director at Curaleaf Clinic and co-author of the study, underscored the significance of these findings in the clinical management of insomnia. He emphasized the importance of monitoring potential tolerance development over time and tailoring treatments on an individual basis to maximize efficacy while mitigating risks. The practical implications for clinicians include the possibility of integrating cannabis-based products as adjunctive or second-line therapy, particularly in patients unresponsive to or intolerant of standard pharmacological options.
The observational nature of this research is both a strength and a limitation. While allowing a realistic picture of patient experiences over an extended period, it inherently cannot establish cause-effect relationships. Confounding variables such as lifestyle changes, placebo effects, and the variability in product formulations and dosages require careful consideration. Nevertheless, the study’s real-world evidence broadens our understanding of medical cannabis’s therapeutic potential, encouraging further rigorously controlled investigations.
From a neurobiological perspective, it has been hypothesized that cannabinoids modulate sleep through their action on CB1 receptors in the central nervous system. These receptors influence neurotransmitters implicated in sleep cycles, such as GABA and glutamate. Moreover, the balance of THC and CBD in medicinal formulations could account for differential effects on sleep latency and maintenance, where THC’s sedative properties complement CBD’s anxiolytic and anti-inflammatory effects, possibly improving sleep architecture and subjective restfulness.
The complex interplay between insomnia, mental health, and pain highlights the multifactorial nature of chronic sleep disorders. Cannabis-based treatments potentially target these overlapping symptoms simultaneously, addressing the limitations of mono-target pharmacotherapeutics. Additionally, favorable patient-reported outcomes may promote adherence, an essential factor often overlooked in clinical trials but critical for real-world success.
As the legal and regulatory landscapes evolve, so too does the urgency to clarify the clinical role of cannabis-based medicinal products. The study’s findings contribute to a growing body of literature advocating for the thoughtful incorporation of these treatments into personalized medicine strategies. However, regulatory agencies and healthcare professionals must weigh these benefits against potential risks, emphasizing careful screening, dosing protocols, and longitudinal follow-up.
In conclusion, this pioneering investigation offers encouraging evidence that cannabis-based medical products can provide meaningful and sustained improvements in sleep quality and associated symptoms over an extended period. While not a panacea, these findings illuminate a promising avenue for patients grappling with the often intractable challenge of insomnia. The research paves the way for future randomized trials that will be critical in defining standardized treatment guidelines and integrating cannabinoid therapies into mainstream clinical practice.
For full access to the study and detailed data, the article appears freely available in PLOS Mental Health, reinforcing the commitment to open science and the dissemination of knowledge that may benefit insomnia patients worldwide.
Subject of Research: People
Article Title: UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia
News Publication Date: 27-Aug-2025
Web References: https://doi.org/10.1371/journal.pmen.0000390
References:
Aggarwal A, Erridge S, Cowley I, Evans L, Varadpande M, Clarke E, et al. (2025) UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia. PLOS Ment Health 2(8): e0000390. https://doi.org/10.1371/journal.pmen.0000390
Image Credits: Photo by Jeff W on Unsplash (free to use under the Unsplash License)
